---
document_datetime: 2025-12-01 16:56:42
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xofluza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xofluza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2230217
conversion_datetime: 2025-12-29 20:32:26.874158
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xofluza

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 27/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314429                     | variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.i Introduction of a new site of micronisation - Accepted   |            |            |                        |                                                                                                                                                                                                                                                                                        |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000246160 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8 and 5.1 of the SmPC in order to update clinical efficacy and safety information based on final results from study MV40618 (Centerstone), a phase 3b, multicenter, randomised, double-blind, placebo-controlled, clinical efficacy study of baloxavir marboxil for the reduction of direct transmission of influenza from otherwise       | 16/10/2025 | 17/11/2025 | SmPC, Labelling and PL | In a phase 3b study of household influenza transmission, treatment emergent mutations, PA/I38M/N/T were detected in 15 of 208 influenza infected index patients (7.2 %) in the baloxavir marboxil group. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | healthy patients to household contacts. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and introduce editorial changes in the PI.                                                                                                                                                                                                                                         |            |            |                        |                                                                                                                                                                                                                                                                       |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000300791 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted | 25/09/2025 | N/A        |                        |                                                                                                                                                                                                                                                                       |
| Renewal - 5 year / EMA/R/0000265299   | - Renewal - Accepted Renewal of marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                 | 18/09/2025 | 17/11/2025 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xofluza in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| Variation type IB / EMA/VR/0000284686 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.d Change in storage conditions of the finished product or the diluted/reconstituted product - Accepted                                                                                                                                                                                                                                       | 31/07/2025 | 17/11/2025 | SmPC                   |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.II.f.1 Change in the shelf-life or storage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| conditions of the finished product - B.II.f.1.e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| B.II.b.3 Change in the manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Change in the holding time of an intermediate - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|